News & Updates
Filter by Specialty:

Tocilizumab with or without MTX for acute RA: Does combo work better than mono?
Subcutaneous tocilizumab, used either as a monotherapy or in combination with methotrexate (MTX), shows greater efficacy than MTX alone in Chinese patients with active rheumatoid arthritis (RA) who have not adequately responded to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
Tocilizumab with or without MTX for acute RA: Does combo work better than mono?
27 Jun 2025
MOSAIC updates: MRI outcomes bolster apremilast role in PsA dactylitis
Apremilast, an oral immunomodulating phosphodiesterase-4 inhibitor, reduces inflammation in individual joints and clinical dactylitis as per MRI in patients with psoriatic arthritis (PsA), according to the results of a dynamic contrast-enhanced MRI (DCE-MRI) analysis of the phase IV, open-label MOSAIC study.
MOSAIC updates: MRI outcomes bolster apremilast role in PsA dactylitis
27 Jun 2025
Diabetes in CHD patients ups risk of hepatocellular carcinoma
The presence of diabetes mellitus predisposes patients with chronic hepatitis B (CHB) to a higher risk of developing hepatocellular carcinoma (HCC), reveals a study presented at EASL 2025.